Composition of T and NK cells immune cell types in patients with AML remains unchanged after short-term venetoclax treatment. (A) Schematic representation of the AML study. PB samples from 16 patients with AML were collected before (pre) and after (post) 7 days of venetoclax treatment and analyzed by CyTOF. (B) Percentages of B cells, NK cells, and T cells from total lymphocytes measured by CyTOF. (C) Mean expression of survival and checkpoint proteins in CD4⁺ and CD8⁺ cells expressed as a ratio of postvenetoclax:prevenetoclax treatment. Each symbol represents an individual patient; paired t test; ∗P < .05, ∗∗P < .01. (D) Representative histograms and mean expression of BCL-2, MCL-1, BCL-XL, CTLA-4, PD-1, TIM-3, PD-L1, CD27, OX40, and T-BET protein expression pre- and postvenetoclax treatment in CD4 naïve (CD45RA^highCD27^highCCR7^high), CD4 EM (CD45RO^high), CD8 naïve (CD45RA^highCD27^highCCR7^high), and CD8 EM (CD45RO^high) cells from patient AML_027.